Results from nonclinical studies of Cidara’s lead candidate CD101 IV (formerly biafungin), a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C. Four posters and one abstract regarding CD101 IV have been accepted for presentation. Kieren Marr, M.D., professor of medicine and oncology, and director of the transplant and oncology infectious diseases program at the Johns Hopkins University School of Medicine…

Veteran team to apply novel, small molecule immunotherapy platform to treat severe fungal infections in immune compromised patients. Cidara has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudbreak™ targeted immunotherapy platform and CD101 IV (formerly biafungin), a novel long acting echinocandin antifungal drug, into human clinical studies. The financing round was led by 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners and also included…